These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28204995)

  • 41. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
    Laporte S; Bertoletti L; Romera A; Mismetti P; Pérez de Llano LA; Meyer G
    Thromb Res; 2012 Dec; 130(6):853-8. PubMed ID: 22939430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
    Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ
    J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of anticoagulant treatment in cancer patients.
    Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW
    Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost of outpatient venous thromboembolism prophylaxis following lower limb injuries.
    Menakaya CU; Pennington N; Muthukumar N; Joel J; Ramirez Jimenez AJ; Shaw CJ; Mohsen A
    Bone Joint J; 2013 May; 95-B(5):673-7. PubMed ID: 23632680
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
    De Stefano V; Ruggeri M; Cervantes F; Alvarez-Larrán A; Iurlo A; Randi ML; Elli E; Finazzi MC; Finazzi G; Zetterberg E; Vianelli N; Gaidano G; Rossi E; Betti S; Nichele I; Cattaneo D; Palova M; Ellis MH; Cacciola R; Tieghi A; Hernandez-Boluda JC; Pungolino E; Specchia G; Rapezzi D; Forcina A; Musolino C; Carobbio A; Griesshammer M; Sant'Antonio E; Vannucchi AM; Barbui T
    Leukemia; 2016 Oct; 30(10):2032-2038. PubMed ID: 27113812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism.
    Bryk AH; Piróg M; Plens K; Undas A
    Vascul Pharmacol; 2016 Dec; 87():242-247. PubMed ID: 27865826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
    Louzada ML; Majeed H; Wells PS
    Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.
    Carson W; Schilling B; Simons WR; Parks C; Choe Y; Faria C; Powers A
    J Pharm Pract; 2012 Apr; 25(2):180-9. PubMed ID: 21987527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients.
    Hale A; Merlo G; Nissen L; Coombes I; Graves N
    BMC Health Serv Res; 2018 Oct; 18(1):749. PubMed ID: 30285744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism.
    Piovella F; Iosub DI
    Thromb Res; 2017 Apr; 152():87-92. PubMed ID: 28017344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
    Bauersachs R
    Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world comparative effectiveness of dalteparin and enoxaparin for venous thromboembolism prophylaxis.
    Di Mauro AL; Austin LJ; Zande J; Winckel K; Neale R; De Guzman KR
    Blood Coagul Fibrinolysis; 2024 Apr; 35(3):101-107. PubMed ID: 38358899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevention of deep vein thrombosis in cancer patients.
    Lee AY
    Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.